First Turn Management LLC Buys 113,550 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

First Turn Management LLC boosted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 53.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 326,494 shares of the company’s stock after purchasing an additional 113,550 shares during the quarter. Vera Therapeutics comprises 2.3% of First Turn Management LLC’s portfolio, making the stock its 23rd largest holding. First Turn Management LLC owned approximately 0.60% of Vera Therapeutics worth $14,431,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Vera Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after buying an additional 350 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new position in Vera Therapeutics during the second quarter worth $135,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vera Therapeutics during the second quarter worth $163,000. Ameritas Investment Partners Inc. grew its holdings in shares of Vera Therapeutics by 20.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after purchasing an additional 688 shares during the last quarter. Finally, Cetera Advisors LLC bought a new stake in shares of Vera Therapeutics during the first quarter worth $235,000. Institutional investors own 99.21% of the company’s stock.

Insider Transactions at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 15,625 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total transaction of $585,937.50. Following the sale, the chief executive officer now owns 307,972 shares in the company, valued at $11,548,950. This represents a 4.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Beth C. Seidenberg sold 1,177 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total value of $49,445.77. Following the sale, the director now owns 160,376 shares in the company, valued at approximately $6,737,395.76. This represents a 0.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 104,398 shares of company stock worth $4,376,163 in the last 90 days. Corporate insiders own 21.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Wedbush boosted their target price on Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Guggenheim boosted their target price on Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 price objective on shares of Vera Therapeutics in a report on Tuesday, October 1st. Finally, Evercore ISI upgraded Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $57.88.

Vera Therapeutics Trading Down 3.1 %

NASDAQ VERA opened at $44.81 on Tuesday. The stock’s 50 day moving average price is $42.70 and its two-hundred day moving average price is $39.45. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a 52 week low of $12.28 and a 52 week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.21). As a group, research analysts forecast that Vera Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.